Kodama N, Furuse K, Kawahara M, Arai R, Yamamoto M, Tsuruta M, Kubota K, Ogawara M, Nakai R, Kawano S
National Kinki Chuo Hospital, Sakai.
Gan To Kagaku Ryoho. 1988 Dec;15(12):3233-7.
Twenty-seven patients with advanced and previously untreated non-small cell carcinoma of the lung received combination chemotherapy with CDDP (100 mg/m2 iv on day 1) and etoposide (100 mg/m2 iv on day 2, 4 and 6). Eleven partial responses were observed (response rate of 40.7%), and the median survival of patients was 44.4 weeks. Toxicity was tolerable with moderate myelosuppression. This combination chemotherapy should be recommended for further clinical trials.
27例晚期且此前未接受过治疗的非小细胞肺癌患者接受了顺铂(第1天静脉注射100mg/m²)和依托泊苷(第2、4和6天静脉注射100mg/m²)联合化疗。观察到11例部分缓解(缓解率为40.7%),患者的中位生存期为44.4周。毒性可耐受,有中度骨髓抑制。这种联合化疗应推荐用于进一步的临床试验。